urogenital cancer
Natera, Alliance for Clinical Trials in Oncology Partner for Urothelial Cancer Study
The study will assess the use of Natera's Signatera assay in guiding treatment among people with muscle-invasive urothelial cancer after bladder removal.
Veracyte Reports 25 Percent Q3 Revenue Growth, Raises Full-Year Guidance
The firm said that its Decipher and Afirma tests each benefited from expanded coverage and largely drove growth this quarter.
Veracyte Q2 Revenues up 32 Percent, Beat Analyst Expectations
The firm said the growth was due primarily to its portfolio of urology tests, which it brought on through its acquisition of Decipher Biosciences.
Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx
The companies will codevelop, validate, and commercialize a companion diagnostic for Acrivon's targeted DNA damage response inhibitor therapy, ACR-368.
OraSure Technologies Acquires CoreBiome, Novosanis
The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.
May 28, 2013